Genomic Medicine Market Size, Share, Opportunities, And Trends By Application (Oncology, Pharmacogenomics, Rare And Undiagnosed Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Others), By Product And Services (Instruments And Equipment, Consumables, Services(Genomic Testing, Data Analysis, Interpretation, Genetic Counselling)), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, Sanger Sequencing, Others), By End-User (Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies), And By Geography - Forecasts From 2024 To 2029

Genomic Medicine Market is expected to grow at a CAGR of 20.61% from a market size of US$15.91 billion in 2022 to reach US$59.07 billion in 2029.

Genomic medicine is changing healthcare. By analyzing an individual's genetic information, genomic medicine provides personalized illness diagnosis, treatment, and prevention. From identifying genetic risk factors to personalizing pharmaceutical regimens, genomics is crucial to improving patient outcomes. 

Due to increased demand for precision treatments and advancements in genomic sequencing technology, the genomic medicine market size is expanding rapidly. The type of test, the complexity of the analysis, and data interpretation all play a role in determining the cost of genetic testing and analysis. For precise cost information, it is best to speak directly with healthcare providers or providers of genetic testing.

Due to advancements in DNA sequencing technology, lower genomic testing costs, and increased awareness of the significance of genetics to human health, the genomic medicine market growth has experienced rapid expansion in recent years.

These developments have resulted in a greater acceptance of genomic medicine across a variety of medical specialties, including rare genetic diseases, cardiology, and neurology. This genomic medicine market has various segments, such as oncology, pharmacogenomics, rare and undiagnosed diseases, infectious diseases, cardiovascular diseases, and neurological disorders.

Market Drivers:

• Advancements in genomic technologies

The development of genomic technology has contributed to the genomic medicine industry expansion. Bioinformatics tools are capable of managing enormous genetic data sets, and next-generation sequencing enables quick and inexpensive DNA analysis. These advancements have expanded the scope of individualized medicine, resulting in improved diagnosis, individualized treatment, and patient outcomes.

• Declining cost of genomic sequencing

Technology has become more accessible and is utilized extensively in medicine and research as the cost of genome sequencing decreases. Both higher production volumes and Moore's Law contribute to cost reduction. Better laboratory procedures and large-scale sequencing programs make it possible to study and analyze the genome at a larger scale, expanding population genomics and individualized therapy.

• Rising chronic diseases

Genomics is playing a pivotal role in the advancement of personalized medicine by providing insights into the molecular intricacies that distinguish individuals. This enables the formulation of tailored predictions regarding disease risk, empowering individuals to select prevention plans suited to their unique needs. Additionally, genomics facilitates the identification of optimal drugs and dosages for individuals, moving away from the conventional "one size fits all" approach to drug therapy.

Noncommunicable diseases (NCDs) account for a staggering 41 million deaths annually, representing 74% of global mortality. Alarmingly, 17 million individuals succumb to NCDs before reaching the age of 70, with 86% of these premature deaths occurring in low- and middle-income countries. Furthermore, 77% of all NCD-related deaths transpire in these regions.

Chronic illnesses such as cancer, heart disease, and diabetes impose a substantial healthcare burden worldwide. Genomic medicine holds immense potential for facilitating earlier disease detection, more accurate prediction of disease susceptibility, and the development of targeted therapies tailored to these conditions.

Market Restraint:

• High cost and complex procedure

Whole-genome sequencing, the most comprehensive form of genetic testing, often comes with a high price tag, which can be a barrier for both individuals and healthcare systems. The complexity of performing genomic tests and procedures necessitates specialized equipment and extensively trained personnel, further adding to the expenses involved. As a result, access to these services may be restricted in settings with limited resources.

Genomic medicine market segmentation by application into oncology, pharmacogenomics, rare and undiagnosed diseases, infectious diseases, cardiovascular diseases, neurological disorders, and others

The genomic medicine market is segmented by application into various categories, including oncology, pharmacogenomics, rare and undiagnosed diseases, infectious diseases, cardiovascular diseases, neurological disorders, and other applications.

In the field of oncology (cancer), genomic medicine plays a crucial role in identifying genetic mutations associated with specific cancers, thereby facilitating the classification of tumors for more targeted therapies and the development of personalized cancer treatment regimens.

Pharmacogenomics involves predicting a patient's response to medications, ensuring their effectiveness while minimizing adverse side effects. This application is particularly beneficial for individuals who may be prone to experiencing unfavorable reactions to certain drugs.

Rare and undiagnosed diseases benefit from genomic medicine through the development of targeted therapies for these often debilitating conditions. Additionally, genetic counseling services are provided to families at risk of passing on rare genetic disorders.

In the realm of infectious diseases, genomic medicine aids in combating evolving pathogens and antibiotic resistance by facilitating the development of more effective vaccines and antimicrobial therapies.

Cardiovascular diseases are addressed through genomic medicine by identifying individuals at higher risk of developing heart disease based on genetic predisposition and understanding the genetic factors influencing medication responses for heart conditions.

Neurological disorders, such as Alzheimer's disease, Parkinson's disease, and ALS, benefit from genomic medicine through the identification of genetic mutations associated with these conditions and the subsequent development of targeted therapies.

Other applications of genomic medicine include detecting potential genetic abnormalities in fetuses during pregnancy, identifying individuals carrying genes for specific genetic disorders before they conceive, and exploring the field of nutrigenomics.

North America and Europe currently hold significant positions in the genomic medicine industry-

Due to a well-established research and application infrastructure, particularly in the United States, North America leads the genomic medicine market share growth. Benefits incorporate the district's strong well-being framework and acknowledgment of customized treatment. However, concerns include issues with the legislation, information confidentiality, and access disparities between demographic groups.

Another important market is Europe, which includes countries like the United Kingdom, Germany, and France. It is known for its sophisticated healthcare systems, government support, and research collaboration networks. Payment procedures, healthcare system harmonization, and data protection regulations are among the difficulties in Europe. Genetic medicine's global success and development depend on overcoming obstacles like data privacy, law, reimbursement, and resource limitations.

Market Developments:

• May 2023-  the advancement and impact of genomic technologies on disease preparation and response are now recognized by Illumina Inc., a global leader in array-based technologies and DNA sequencing. Genomic technologies have begun enabling healthcare agencies and healthcare organizations to better plan for and respond to pathogenic threats since the COVID-19 pandemic's rise in sequencing facilities and capabilities.
• April 2023- Illumina Inc., a worldwide trailblazer in DNA sequencing and cluster-based innovation, and Henry Portage Wellbeing, a philanthropic association in the Detroit metro district, reported the development of a joint effort to assess the impact of exhaustive genomic testing in cardiovascular sickness. The first trial under this new partnership, CardioSeq, included 1,500 patients receiving care from Henry Ford's Division of Cardiovascular Medicine. 

Genomic Medicine Market Scope:

 

Report Metric	Details
Market Size Value in 2022	US$15.91 billion
Market Size Value in 2029	US$59.07 billion
Growth Rate	CAGR of 20.61% from 2022 to 2029
Study Period	2019 to 2029
Historical Data	2019 to 2022
Base Year	2023
Forecast Period	2024 – 2029
Forecast Unit (Value)	USD Billion
Segments Covered	Application Products And Services Technology End-User Geography
Companies Covered	Illumina, Inc. Thermo Fisher Scientific, Inc. F. Hoffmann-La Roche Ltd. QIAGEN N.V. Pacific Biosciences of California, Inc.
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope	Free report customization with purchase

 

Market Segmentation:

• By Application
  • Oncology
  • Pharmacogenomics
  • Rare and Undiagnosed Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Others     
• By Products And Services
  • Instruments and Equipment
  • Consumables
  • Services (Genomic Testing, Data Analysis, Interpretation, Genetic Counselling)   
• By Technology
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Sanger Sequencing
  • Others   
• By End-user
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical and Biotechnology Companies
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy 
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China 
    • Japan
    • India
    • South Korea
    • Indonesia
    • Taiwan
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits to the stakeholder

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GENOMIC MEDICINE MARKET BY APPLICATION

5.1. Introduction

5.2. Oncology

5.2.1. Market opportunities and trends

5.2.2. Growth prospects

5.2.3. Geographic lucrativeness 

5.3. Pharmacogenomics

5.3.1. Market opportunities and trends

5.3.2. Growth prospects

5.3.3. Geographic lucrativeness 

5.4. Rare and Undiagnosed Diseases

5.4.1. Market opportunities and trends

5.4.2. Growth prospects

5.4.3. Geographic lucrativeness 

5.5. Infectious Diseases

5.5.1. Market opportunities and trends

5.5.2. Growth prospects

5.5.3. Geographic lucrativeness 

5.6. Cardiovascular Diseases

5.6.1. Market opportunities and trends

5.6.2. Growth prospects

5.6.3. Geographic lucrativeness 

5.7. Neurological Disorders

5.7.1. Market opportunities and trends

5.7.2. Growth prospects

5.7.3. Geographic lucrativeness 

5.8. Others

5.8.1. Market opportunities and trends

5.8.2. Growth prospects

5.8.3. Geographic lucrativeness 

6. GENOMIC MEDICINE MARKET BY PRODUCTS AND SERVICES

6.1. Introduction

6.2. Instruments and Equipment

6.2.1. Market opportunities and trends

6.2.2. Growth prospects

6.2.3. Geographic lucrativeness 

6.3. Consumables

6.3.1. Market opportunities and trends

6.3.2. Growth prospects

6.3.3. Geographic lucrativeness 

6.4. Services (Genomic Testing, Data Analysis, Interpretation, Genetic Counselling)

6.4.1. Market opportunities and trends

6.4.2. Growth prospects

6.4.3. Geographic lucrativeness 

7. GENOMIC MEDICINE MARKET BY TECHNOLOGY

7.1. Introduction

7.2. Next-Generation Sequencing (NGS)

7.2.1. Market opportunities and trends

7.2.2. Growth prospects

7.2.3. Geographic lucrativeness 

7.3. Polymerase Chain Reaction (PCR)

7.3.1. Market opportunities and trends

7.3.2. Growth prospects

7.3.3. Geographic lucrativeness 

7.4. Microarray

7.4.1. Market opportunities and trends

7.4.2. Growth prospects

7.4.3. Geographic lucrativeness 

7.5. Sanger Sequencing

7.5.1. Market opportunities and trends

7.5.2. Growth prospects

7.5.3. Geographic lucrativeness 

7.6. Others

7.6.1. Market opportunities and trends

7.6.2. Growth prospects

7.6.3. Geographic lucrativeness 

8. GENOMIC MEDICINE MARKET BY END-USER

8.1. Introduction

8.2. Hospitals and Clinics

8.2.1. Market opportunities and trends

8.2.2. Growth prospects

8.2.3. Geographic lucrativeness 

8.3. Diagnostic Laboratories

8.3.1. Market opportunities and trends

8.3.2. Growth prospects

8.3.3. Geographic lucrativeness 

8.4. Research Institutes

8.4.1. Market opportunities and trends

8.4.2. Growth prospects

8.4.3. Geographic lucrativeness 

8.5. Pharmaceutical and Biotechnology Companies

8.5.1. Market opportunities and trends

8.5.2. Growth prospects

8.5.3. Geographic lucrativeness 

9. GENOMIC MEDICINE MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Application

9.2.2. By Products And Services

9.2.3. By Technology

9.2.4. By End-user

9.2.5. By Country

9.2.5.1. United States

9.2.5.1.1. Market Trends and Opportunities

9.2.5.1.2. Growth Prospects

9.2.5.2. Canada

9.2.5.2.1. Market Trends and Opportunities

9.2.5.2.2. Growth Prospects

9.2.5.3. Mexico

9.2.5.3.1. Market Trends and Opportunities

9.2.5.3.2. Growth Prospects

9.3. South America

9.3.1. By Application

9.3.2. By Products And Services

9.3.3. By Technology

9.3.4. By End-user

9.3.5. By Country

9.3.5.1. Brazil

9.3.5.1.1. Market Trends and Opportunities

9.3.5.1.2. Growth Prospects

9.3.5.2. Argentina

9.3.5.2.1. Market Trends and Opportunities

9.3.5.2.2. Growth Prospects

9.3.5.3. Others

9.3.5.3.1. Market Trends and Opportunities

9.3.5.3.2. Growth Prospects

9.4. Europe

9.4.1. By Application

9.4.2. By Products And Services

9.4.3. By Technology

9.4.4. By End-user

9.4.5. By Country

9.4.5.1. Germany

9.4.5.1.1. Market Trends and Opportunities

9.4.5.1.2. Growth Prospects

9.4.5.2. France

9.4.5.2.1. Market Trends and Opportunities

9.4.5.2.2. Growth Prospects

9.4.5.3. UK

9.4.5.3.1. Market Trends and Opportunities

9.4.5.3.2. Growth Prospects

9.4.5.4. Spain

9.4.5.4.1. Market Trends and Opportunities

9.4.5.4.2. Growth Prospects

9.4.5.5. Italy

9.4.5.5.1. Market Trends and Opportunities

9.4.5.5.2. Growth Prospects

9.4.5.6. Others

9.4.5.6.1. Market Trends and Opportunities

9.4.5.6.2. Growth Prospects

9.5. Middle East and Africa

9.5.1. By Application

9.5.2. By Products And Services

9.5.3. By Technology

9.5.4. By End-user

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.1.1. Market Trends and Opportunities

9.5.5.1.2. Growth Prospects

9.5.5.2. UAE

9.5.5.2.1. Market Trends and Opportunities

9.5.5.2.2. Growth Prospects

9.5.5.3. Others

9.5.5.3.1. Market Trends and Opportunities

9.5.5.3.2. Growth Prospects

9.6. Asia Pacific

9.6.1. By Application

9.6.2. By Products And Services

9.6.3. By Technology

9.6.4. By End-user

9.6.5. By Country

9.6.5.1. China

9.6.5.1.1. Market Trends and Opportunities

9.6.5.1.2. Growth Prospects

9.6.5.2. Japan

9.6.5.2.1. Market Trends and Opportunities

9.6.5.2.2. Growth Prospects

9.6.5.3. India

9.6.5.3.1. Market Trends and Opportunities

9.6.5.3.2. Growth Prospects

9.6.5.4. South Korea

9.6.5.4.1. Market Trends and Opportunities

9.6.5.4.2. Growth Prospects

9.6.5.5. Indonesia

9.6.5.5.1. Market Trends and Opportunities

9.6.5.5.2. Growth Prospects

9.6.5.6. Taiwan

9.6.5.6.1. Market Trends and Opportunities

9.6.5.6.2. Growth Prospects

9.6.5.7. Others

9.6.5.7.1. Market Trends and Opportunities

9.6.5.7.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisition, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Illumina, Inc.

11.2. Thermo Fisher Scientific, Inc.

11.3. F. Hoffmann-La Roche Ltd.

11.4. QIAGEN N.V.

11.5. Pacific Biosciences of California, Inc.

11.6. BGI Genomics

11.7. Oxford Nanopore Technologies Ltd.

11.8. PerkinElmer, Inc.

11.9. Bio-Rad Laboratories, Inc.

11.10. Agilent Technologies, Inc.

Illumina, Inc.

Thermo Fisher Scientific, Inc.

F. Hoffmann-La Roche Ltd.

QIAGEN N.V.

Pacific Biosciences of California, Inc.

BGI Genomics

Oxford Nanopore Technologies Ltd.

PerkinElmer, Inc.

Bio-Rad Laboratories, Inc.

Agilent Technologies, Inc.